GOOIMEER 2-35, NARRDEN, P7
Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
Other Events
Appointment of Robert W. Gunning as Principal Accounting Officer
Earnings Release
Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
COO Douglas Kling Resigns; Transition to CEO Role at Another Company
News, Material Contracts
Provides Corporate Update and Reports First Quarter Financial Results
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Notice of Proposed Sale of Securities
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload